Literature DB >> 29547919

Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors.

Ian Thompson1, Phyllis Goodman2, Catherine Tangen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29547919      PMCID： PMC6454440          DOI： 10.1093/jnci/djy038

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; M Scott Lucia; Phyllis J Goodman; John J Crowley; Howard L Parnes; Charles A Coltman
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

2.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Authors:  Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

Review 3.  Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.

Authors:  Catherine M Tangen; Phyllis J Goodman; Cathee Till; Jeannette M Schenk; M Scott Lucia; Ian M Thompson
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

4.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

5.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

6.  Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.

Authors:  Anna Wallerstedt; Peter Strom; Henrik Gronberg; Tobias Nordstrom; Martin Eklund
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

Review 7.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

8.  Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Authors:  M Scott Lucia; Amy K Darke; Phyllis J Goodman; Francisco G La Rosa; Howard L Parnes; Leslie G Ford; Charles A Coltman; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2008-05-18

9.  Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

Authors:  Mary W Redman; Catherine M Tangen; Phyllis J Goodman; M Scott Lucia; Charles A Coltman; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2008-05-18

10.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.